Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review

SIMPLE SUMMARY: Apalutamide, darolutamide and enzalutamide are androgen-receptor signaling inhibitors proved to be useful in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Although computed tomography and bone scans have been used to identify patients with nmCRPC in pivot...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattrini, Carlo, Caffo, Orazio, De Giorgi, Ugo, Mennitto, Alessia, Gennari, Alessandra, Olmos, David, Castro, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997634/
https://www.ncbi.nlm.nih.gov/pubmed/35406564
http://dx.doi.org/10.3390/cancers14071792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997634/
https://www.ncbi.nlm.nih.gov/pubmed/35406564
http://dx.doi.org/10.3390/cancers14071792

Ejemplares similares